818TiP Balstilimab alone or in combination with zalifrelimab as second-line treatment for patients with previously treated recurrent/metastatic cervical cancer (R/M CC): A randomized, placebo-controlled phase II trial (RaPiDS/GOG-3028)
Year: 2021
Type: article
Source: Annals of Oncology
Authors: L. Randall, D. O'Malley, C. Gunderson Jackson, R.L. Coleman, J. Hays, K.N. Moore, R.W. Naumann, R. Rocconi, B. Slomovitz, K.S. Tewari, M. Ancukiewicz, W.I. Ortuzar Feliu, B.J. Monk
Institutions: Virginia Commonwealth University, VCU Massey Comprehensive Cancer Center, Virginia Commonwealth University Medical Center, The Ohio State University Wexner Medical Center, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, University of Oklahoma, Texas Oncology, The Ohio State University, Levine Cancer Institute, USA Mitchell Cancer Institute, University of South Alabama, University of Miami, University of Miami Health System, Sylvester Comprehensive Cancer Center, University of California, Irvine, Agenus (United States), The US Oncology Network, Arizona Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3203581678